Macquarie Group LTD Akero Therapeutics, Inc. Call Options Transaction History
Macquarie Group LTD
- $90.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
194Shares Held
74.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$404 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$362 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$303 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$286 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$268 Million5.21% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.37B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...